Abstract 2034
Background
Although there are increasing evidences of lncRNA role in cancer progression, and of its possible diagnostic and therapeutic significance, lncRNA in thyroid neoplasms are poorly investigated: studies are limited to papillary cancer, the differences in variants of papillary carcinoma are rarely considered, there are no investigations of lncRNA in benign nodules, follicular and anaplastic carcinomas.
Methods
To evaluate lncRNA expression in follicular adenoma (FA), follicular and classical variants of papillary carcinoma (fvPTC/clPTC), follicular (FTC) and anaplastic (ATC) carcinomas, a comprehensive dataset of 8 independent Microarray experiments on Affymetrix Human Genome U133 Plus 2.0 Array and RNA-Seq experiments (TCGA and PRJEB11591 projects) was analyzed. In silico validation of differential expression was performed. Putative functions of aberrantly expressed lncRNA were determined via co-expression and enrichment analysis of Gene Ontology, KEGG, Reactome terms.
Results
The analysis revealed 8 lncRNA general for all investigated neoplasms, 22 - general for papillary carcinomas, 32 - specific for clPTC, 1 - for fvPTC, and 177 - specific for ATC. No lncRNA differentially expressed in FTC and FA was found. There are strong clustering of ATC, clustering of clPTC and fvPTC, no clustering within the FTC and FA. LncRNA found to be specific for ATC are probably associated with anaplastic features and cancer progression. Potential functions of lncRNA general for all studied neoplasms - L1CAM interactions; general for papillary carcinomas - tryptophan metabolism; specific for fvPTC - cell polarity and WNT signaling; specific for clPTC - extracellular matrix organization and endoderm formation; specific for ATC - cell cycle and mitosis. Known oncogenic and tumor suppressor lncRNA (NR2F1-AS1, LINC00511, SLC26A4-AS1, CRNDE, LINC01116, RMST) are found in thyroid carcinomas for the first time.
Conclusions
Common and specific patterns of lncRNA expression in main histological subtypes of thyroid nodules are determined. The findings enhance the understanding of lncRNA in thyroid cancer progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4991 - Relation between objective tumor shrinkage and progression-free survival (PFS) in the NETTER-1 population
Presenter: Marianne Pavel
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5796 - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors (STs) and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Antoine Hollebecque
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3199 - SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE)
Presenter: Enrique Grande
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
Slides
5891 - New circulating biomarkers in Gastro-Entero-Pancreatic-Neuroendocrine-Tumors
Presenter: Martine Bocchini
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
1590 - Longitudinal Increase in Ki67 and High-grade Transformation in Pancreatic Neuroendocrine Tumors (PNETs)
Presenter: Johan Botling
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3362 - Impact of lung metastasis on overall survival (OS) in the phase 3 SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
Presenter: Makoto Tahara
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3665 - Prescription and Treatment Patterns of Lenvatinib (L) in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer (rDTC): A Retrospective Analysis of the Canadian Patient Support Program (PSP)
Presenter: Sebastien Hotte
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5072 - Spatiotemporal intratumor genetic heterogeneity and clonal evolution in PTCs and paired DM
Presenter: Sara Gil Bernabé
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
Poster Discussion – NETs and endocrine tumours - Invited Discussant 1382PD, 1383PD and 1834PD
Presenter: Nicola Fazio
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Slides
Webcast
Poster Discussion – NETs and endocrine tumours - Invited Discussant 1385PD and 1386PD
Presenter: Rocio Garcia-Carbonero
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Slides
Webcast